Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27936741 | 0.88 | GPBAR1 (0.62) | HSD17B10MEN1GAAKMT2AGPBAR1 | |
| SCHEMBL2470614 | 0.87 | GPBAR1 (0.60) | HSD17B10MEN1GAAKMT2AGPBAR1 | |
| SCHEMBL3826089 | 0.87 | GPBAR1 (0.60) | HSD17B10MEN1GAAKMT2AGPBAR1 | |
| SCHEMBL30395326 | 0.87 | GPBAR1 (0.60) | HSD17B10MEN1GAAKMT2AGPBAR1 | |
| SCHEMBL5773636 | 0.83 | GPBAR1 (0.57) | HSD17B10MEN1KMT2AGPBAR1TSHR | |
| SCHEMBL11408570 | 0.83 | EPAS1 (0.61) | HSD17B10MEN1KMT2AGPBAR1EPAS1 | |
| SCHEMBL903109 | 0.82 | HSD17B10 (1.00) | HSD17B10MEN1GAAKMT2AGPBAR1 | |
| SCHEMBL19033 | 0.82 | HSD17B10 (0.65) | HSD17B10MEN1GAAKMT2AGPBAR1 | |
| SCHEMBL2473847 | 0.82 | GPBAR1 (0.56) | HSD17B10GPBAR1TSHREPAS1ALDH1A1 | |
| SCHEMBL2924198 | 0.81 | GPBAR1 (0.58) | GAAGPBAR1TSHREPAS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2096111-A1 | PYRAZOLES AND USE THEREOF AS DRUGS | Japan Tobacco Inc. (JP) | 2009-09-02 | — | — | EP | claimed |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | JAPAN TOBACCO, INC. (JP) | 2009-02-05 | — | — | US | claimed |
| EP-2096111-A1 | PYRAZOLES AND USE THEREOF AS DRUGS | Japan Tobacco Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | JAPAN TOBACCO, INC. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036450-A1 | PYRAZOLE COMPOUNDS AND USE THEREOF | PYGL, GYS2, G6PC1 | HSD17B10 327/4885MEN1 3728/4885GAA 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.